Dr Hartmut Kristeleit Patient case study

 

Indications:1

 

Advanced breast cancer (aBC)
KISQALI® (ribociclib) is indicated for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor (AI) or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy (ET).

  • In pre/perimenopausal women, the ET should be combined with a luteinising hormone-releasing hormone (LHRH) agonist

KISQALI is not recommended to be used in combination with tamoxifen.

Click the play button to watch Dr Kristeleit as he provides his insights into the complexities of navigating changing disease characteristics and treatment priorities over time. He focuses on the treatment of a 60-year-old patient with HR+/HER2– aBC who experienced significant liver metastasis.

Learn more about the safety profile of KISQALI in aBC

Fine out more

Learn more about efficacy in postmenopausal women with HR+/HER2– aBC

Find out more

aBC, advanced breast cancer; AI, aromatase inhibitor; ET, endocrine therapy; HER2–, human epidermal growth factor receptor 2-negative; HR+, hormone receptor-positive; LHRH, luteinising hormone-releasing hormone.

 

Reference

  1. KISQALI® (ribociclib) Summary of Product Characteristics.

 

UK | January 2026 | FA-11555496

 

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email [email protected] or call 01276 698370.